China’s InnoCare Pharma Turns a Profit in First Half Due to Surging Overseas Licensing RevenueYicai·3 hours ago09969-1.08%688428+0.55%
SDIC Securities Remains a Buy on InnoCare Pharma Ltd. (9969)Tip Ranks·1 day ago, 05:45 AM09969-1.08%688428+0.55%
InnoCare Pharma: Revenue up 55.5% and net profit reached RMB 240M, with robust pipeline progress and outlookQuartr·Aug 24 at 10:51 AM09969-1.08%688428+0.55%
InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones AchievedUnusual Whales·Aug 24 at 09:35 AM09969-1.08%688428+0.55%
InnoCare swings to profit of RMB 239.7 million in H1 FY26; revenue climbs 55.5% to RMB 1.1 billionPUBT·Aug 24 at 09:33 AM09969-1.08%688428+0.55%
InnoCare Pharma: Achieved profitability on 55.5% revenue growth, led by drug sales and pipeline progressQuartr·Aug 24 at 04:41 AM09969-1.08%688428+0.55%
China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AMLPUBT·Aug 17 at 08:49 PM09969-1.08%688428+0.55%
InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in ChinaGlobeNewswire·Aug 17 at 08:49 PM09969-1.08%688428+0.55%
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in ChinaGlobeNewswire·Aug 3 at 09:48 PM09969-1.08%688428+0.55%
InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory FilingTip Ranks·Jul 27 at 04:37 AM09969-1.08%688428+0.55%
